International Conference and Exhibition on Cancer & Therapeutics

Cancer Immunology.

• 2019 Ligue Contre le cancer. What are the epigenetic mechanisms involved in chronic lymphocytic leukemia in terms of disease progression?
• 2018 Association Française du Gougerot-Sjogren et des syndromes secs. An implication of epigenetism in the development of B lymphomas during the development of Gougerot Sjogren syndrome.
• 2015 Bourse contract doctoral de establishment.
• 2015 Association Laurette Fugain. Study of the influence of epigenetics on the development of chronic lymphoid leukemia in order to offer personalized therapies.

•  https://publons.com/researcher/1386785/anne-bordron/.
• Immunology 2019, Clinical Reviews in Allergy and  Immunology 2018.
• Aging of 2018.
• Oncotarget 2019, 2018, 2017.
• Cancer Immunology Immunotherapy 2018, 2017.
• Experimental biology and medicine 2016, 2015.
   

1. Mohr A, Cumin M, Bagacean C, Pochard P, Le Dantec C, Hillion S, Renaudineau Y, Berthou C, Temescal A, Saad H, Pers JO, Jamin C, Bordron A, the last two senior authors contributed equally to this work. The regulatory capacity of B cells directs the aggressiveness of CLL. OncoImmunology. 2019;8 (3), 1554968. (IF 5.503).
2.Bagacean C, Temescal A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrenghea M, Berthou C, Paintaud G, Renaudineau Y. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia. J Immunother Cancer. 2019;7(1):22. Doi: 10.1186/s40425-019-0509-0. (IF 8.374).
3.Bordron A, Bagacean C, Mohr A, Temescal A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y. Resistance to complement activation, cell membrane hypersialylation, and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy. Oncotarget. 2018;9(60):31590-31605. Doi: 10.18632/oncotarget.25657. (IF 5.168).
4.Bagacean C, Temescal A, Le Dantec C, Bordron A, Morh A, Saad H, Olivier V, Zdrenhea M, Cristea V, Cartron PF, Douet-Guilbert N, Berthou C, Renaudineau Y. Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia. Oncotarget. 2017;8(39):65699-716. https://doi.org/10.18632/oncotarget. 20081. (IF 5.168).
5.Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M, Cristea V, Douet-Guilbert N, Renaudineau Y. Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion. Clin Epigenetics. 2017;9:122. Doi: 10.1186/s13148-017-0422-7. (IF 6.091).
6. Charras A, Konsta OD, Le Dantec C, Bagacean C, Kapsogeorgou EK, Tzioufas AG, Pers JO, Renaudineau Y, Bordron A, the last two senior authors contributed equally to this work. Cell-specific epigenome-
wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjogren's syndrome. Ann Rheum Dis. 2017;76(3):625-8. Doi:10.1136/annrheumdis-2016-210167. (IF 12.811).
7.Konsta OD, Charras A, Le Dantec C, Kapsogeorgeou E, Bordron A, Brooks WH, Tzioufas AG, Pers JO, Renaudineau Y. Epigenetic modifications in salivary glands from patients with Sjögren's syndrome affect cytokeratin 19 expressions. Bull Group Int Rech Sci Stomatol Odontol. 2016;53(1):e01.
8.Konsta OD, Le Dantec C, Charras A, Brooks WH, Arleevskaya MI, Bordron A, Renaudineau Y. An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren's Syndrome Patients. Front Immunol. 2015;26;6:437. (IF 5.511).
9. Bordron A, Remy-Neris O, De Parscau L. Analyses des differents systems devote an l’UFR Medicine de Brest. Actes IV QPES. 2015;898-904.